source
- Biogen’s experimental Alzheimer’s drug diranersen slows cognitive decline in Phase 2, matching approved therapiesBiogen reported that its experimental Alzheimer’s therapy diranersen slowed cognitive decline in a mid-stage Phase 2 study, achieving decline rates similar to those seen with drugs already on the m…
- Former FDA toxicologist says agency approved Zyn nicotine pouches without fully knowing their compositionFormer FDA toxicologist Christy Leppanen alleges the agency authorized Zyn nicotine pouches without complete safety data on the pouch material. Leppanen, who led a microplastics exposure project a…